Saturday, October 13, 2012

Odanacatib Trial Update

Just a quick update on Odanacatib, the osteoporosis medication currently in phase III trials. Odanacatib works by blocking the bone-degrading enzyme cathepsin K. Merck has just announced that they are mid-stage in their 24-month trial which includes 243 women with osteoporosis. All of the participants in the study have previously been treated with alendronate. Results at this point show the following improvements in bone mineral density:  total hip increase of 0.83%, lumbar spine increase of 2.28%, no increase is noted thus far in the forearm.
Website design and website development by Confluent Forms LLC, Easthampton MA